Leadership Shakeup Across 18 Prominent Pharma Companies in Half a Month, Involving Four Chairpersons

Source: PharmaCube Info

Author: Sunshine

In the blink of an eye, half of November has passed. Following the previous tally of executive changes at the beginning of the month, there have been personnel changes among executives in 18 companies in just half a month.

Foreign Executives Move to Local Pharmaceutical Companies, Multiple Chief Financial Officers and Chief Commercial Officers Resign, (Vice) Chairmen Change... Amid Industry Development and Policy Promotion, Talent Mobility in the Pharmaceutical Circle Seems to Have Become the Norm.

Li Jinhui Appointed as General Manager of Pfizer's Hospital Emergency Division

On November 1, Ms. Li Jinhui, the current General Manager of Oncology and Rare Diseases, was appointed as the General Manager of the Hospital Emergency Division. She will report to Mr. Jean-Christophe Pointeau, President of Pfizer China, and her workplace will be in Beijing. Ms. Li Jinhui will immediately begin the handover process and design the next level of organizational structure to ensure that the new structure for all departments takes effect on December 1.

Li Jinhui joined Pfizer in 1998 and has since been responsible for the sales management of Pfizer China's product lines across several major disease areas, including anti-infectives, cardiovascular, pain, oncology, and rare diseases.

AstraZeneca China Vice President Du Haochen Resigns to Join BeiGene

On November 1, Du Haochen, Vice President of AstraZeneca China and Head of the County Business Department, resigned. He is the fifth senior executive to leave AstraZeneca in the past two months.

Recently, Wu Xiaobin, President of BeiGene, announced to employees that Du Haochen will officially serve as the head of BeiGene's broad market starting from November 18, 2021, and his workplace will be in Shanghai.

Resignation of WOO SWEE LIAN, Chairman of Ruizhi Medicine

On November 1, ChemPartner announced that Mr. WOO SWEE LIAN had applied to resign from his positions as chairman of the board, director, and chairman of the board's strategy committee due to personal reasons. After resignation, he will continue to serve as the company’s strategic advisor.

Long Jiang Appointed as Chief Financial Officer of I-Mab, and Jielun Zhu Appointed as Chief Strategy Officer

On November 1, I-Mab announced two senior executive appointments: Jiang Long as the company's Chief Financial Officer and joining the company’s Board of Directors, taking full responsibility for the company's capital market operations, investor relations, and financial management, reporting directly to Dr. Jingwu Zang, the company's founder and Chairman; Jielun Zhu transitions to the role of Chief Strategy Officer, focusing on planning and advancing corporate development strategies, major strategic initiatives (including global collaborations, strategic investments, and potential mergers and acquisitions), as well as early-stage venture investments.

Ascentage Pharma Chief Financial Officer Zhang Su Resigns

On November 1, Ascentage Pharma announced that Zhang Su had applied to resign from his position as Chief Financial Officer due to "wanting to devote more time and energy to other businesses."

WuXi Biologics CFO Shaohua Lu Retires, Tu Ming Takes Over

On November 1, WuXi Biologics announced that Lu Shaohua had retired and resigned from her position as the company's Chief Financial Officer to devote more time to her personal affairs. Tu Ming has taken over as the Chief Financial Officer of WuXi Biologics and will be responsible for overseeing financial strategy, performance, reporting, business planning, and operational support functions such as capital, tax, accounting management, and auditing.

China National Pharmaceutical Group Vice President Zhou Song Resigns

On November 1, Sinopharm Holdings announced that Mr. Zhou Song had resigned from his position as vice president of the company and all other positions due to a work transfer.

Kangzhi Pharmaceutical Internal Audit and Supervision Department Head Zhou Rongwei Resigns, Li Rui Takes Over

On November 1, Kangzhi Pharmaceutical announced that Mr. Zhou Rongwei had applied to resign from his position as the head of the company's internal audit and supervision department due to personal reasons. After his resignation, he will no longer hold any position in the company. Li Rui has taken over and is responsible for the company’s internal audit and supervision work.

Jinshi Yaya's Director and Vice General Manager (Vice President) Zheng Zhiyong Resigns

On November 1, Jinshi Asia Pharma announced that Mr. Zheng Zhiyong had applied to resign from his position as Vice General Manager (Vice President) of the company due to personal reasons. After resignation, he will continue to serve as a director of the Fourth Board of Directors and a member of the Nomination Committee of the Board.

Han Jing Appointed as Chief Commercial Officer of Alphamab Oncology

On November 2, Alphamab Oncology announced that Han Jing has been appointed as Chief Commercial Officer, mainly responsible for the company's commercial promotion matters, and will report directly to Dr. Xu Ting, Chairman and President.

Han Jing graduated from the Clinical Medicine program at Shanghai Second Medical University. She has held positions such as Regional Manager at Boehringer Ingelheim, Regional Sales Director at AstraZeneca, Regional Sales Director at Bayer, Senior Sales Director of BUO2 at Roche Pharmaceuticals, Vice General Manager at Junshi Biosciences, and Senior Vice President at Genor Biopharma.

Chief Business Officer Qian Wei resigns, Li Cong serves as Co-CEO of the company

On November 3, Junshi Biosciences announced that Chief Commercial Officer Wei Qian had applied for resignation due to personal development reasons, with the last working day being November 12, 2021.

Executive Director Li Cong will be appointed as Co-CEO, overseeing sales. Li Cong has previously served as Sales Director of Novo Nordisk's Shanghai office, as well as Regional Manager, Marketing Director, General Manager Assistant, and General Manager of Tonghua Dongbao in East China.

Shen Wei Yi serves as the Vice Chairman of Stahl.

On November 4, Staille issued an announcement stating that due to the resignation of the former chairman Mr. Hu Jinsen on September 15, 2021, Mr. Hu Jian was appointed as the new chairman of the company, and his position as vice chairman was automatically removed. Therefore, Mr. Shen Weiye was elected as the new vice chairman.

Shen Weiye joined Staley in September 2009, serving successively as Project Manager, Deputy Director, and Director of the Pharmaceutical Chemistry Department, as well as Vice President of the Research Institute. He is currently a director of the company and President of the Research Institute.

Wang Yangzhou Appointed as CEO of BoTeng Bio

On November 8, Bo-Tech Bio announced the appointment of Dr. Wang Yangzhou as the company's Chief Executive Officer, who will be fully responsible for the operation and management of Bo-Tech Bio and accelerate the construction of an end-to-end gene and cell therapy CDMO platform.

Dr. Wang Yangzhou graduated from the Department of Cell and Molecular Biology at the State University of New York, with over 20 years of experience in operational management, business development, and capital market mergers and financing in international biotech and pharmaceutical R&D service companies.

Fosun Pharma Non-Executive Directors Gong Ping and Zhang Houlin Resign

On November 9, Fosun Pharma announced that due to work arrangement adjustments, Mr. Gong Ping and Mr. Zhang Houlin have resigned from their positions as non-executive directors, and Mr. Gong Ping has also resigned from his position as a member of the Board Audit Committee.

Hengrui Medicine CFO Zhou Song Resigns

On November 12, Hengrui announced that Mr. Zhou Song had applied to resign from his position as the company's Chief Financial Officer due to personal reasons. After resigning from the aforementioned position, Mr. Zhou Song will continue to work within the company.

Vice Chairman of Wuhan Pharmaceutical Yao Jianlin Resigns

On November 12, Wuhan Zhongnan Pharmaceutical announced that Mr. Yao Jianlin has applied to resign from his positions as vice chairman and director of the company due to reaching retirement age. He also resigned as a member of the company's board of directors' Enterprise Development and Strategic Investment Committee.

WanTai Bio Board Secretary Ye Fang Resigns

On November 12, Wantai Bio announced that Ms. Ye Fang applied to resign from the position of the company's Board Secretary due to personal career planning. During the vacancy of the Board Secretary, Mr. Qiu Zixin, the chairman, will act as the Board Secretary.

Chairman of the First Medicine, Xu Ziying, Resigns

On November 13, the First Medicine announced that Ms. Xu Ziying had applied to resign from her positions as the Chairman of the Board, Director, Chairman of the Strategic Committee, and member of the Compensation and Evaluation Committee of the Ninth Board of Directors due to work reasons. After her resignation, she will no longer hold any position in the company.